Bausch + Lomb

BLCO · NYSE

$17.47+$0.04 (+0.23%)TodayMarket closed · Oct 23, 7:32 PM ET

Prev close $17.43

Latest news

NewsOct 19, 2:46 PM ETLekha Gupta
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up
NewsOct 12, 2:13 PM ETNeeraj Jain
Why Is Bausch + Lomb Stock Falling Monday?
Press releaseOct 12, 6:45 AM ETBusiness Wire
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Press releaseOct 6, 4:30 PM ETBusiness Wire
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Press releaseOct 5, 7:30 AM ETBusiness Wire
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
NewsSep 18, 11:54 AM ETVandana Singh
‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search
Press releaseSep 11, 6:11 AM ETBusiness Wire
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
Press releaseSep 2, 7:00 AM ETBusiness Wire
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
Press releaseSep 1, 6:58 AM ETBusiness Wire
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
NewsAug 25, 8:23 AM ETVandana Singh
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
Press releaseAug 24, 4:30 PM ETBusiness Wire
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
NewsAug 17, 8:58 AM ETSurbhi Jain
Carl Icahn Trims JetBlue, AEP Stakes While Sitting Out New Stock Bets
Press releaseAug 6, 7:04 AM ETPRNewswire
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
Press releaseAug 6, 7:00 AM ETBusiness Wire
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
NewsJul 29, 7:01 AM ET
Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B Estimate
Press releaseJul 29, 6:58 AM ETBusiness Wire
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
Press releaseJul 16, 7:00 AM ETBusiness Wire
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
NewsJul 10, 10:23 AM ETVandana Singh
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus
Press releaseJul 9, 4:30 PM ETBusiness Wire
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Press releaseJul 9, 7:00 AM ETBusiness Wire
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
Press releaseJul 6, 7:15 AM ETBusiness Wire
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
Press releaseJul 1, 7:00 AM ETBusiness Wire
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
Press releaseJun 1, 6:59 AM ETBusiness Wire
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
Press releaseMay 21, 7:15 AM ETBusiness Wire
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseMay 20, 4:49 PM ETBusiness Wire
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
Press releaseMay 19, 7:00 AM ETBusiness Wire
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
Press releaseMay 7, 7:00 AM ETBusiness Wire
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
Press releaseApr 30, 7:00 AM ETBusiness Wire
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026
NewsApr 29, 7:00 AM ET
Bausch & Lomb Q1 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $1.244B Beat $1.218B Estimate
Press releaseApr 29, 6:58 AM ETBusiness Wire
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
Press releaseApr 23, 7:00 AM ETBusiness Wire
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
Press releaseApr 22, 7:15 AM ETBusiness Wire
Bausch + Lomb Releases 2025 Sustainability Impact Report
NewsMar 24, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseFeb 18, 6:58 AM ETBusiness Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
Press releaseNov 13, 7:00 AM ETBusiness Wire
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
Press releaseOct 29, 6:58 AM ETBusiness Wire
Bausch + Lomb Announces Third-Quarter 2025 Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up

Why Is Bausch + Lomb Stock Falling Monday?

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Carl Icahn Trims JetBlue, AEP Stakes While Sitting Out New Stock Bets

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B Estimate

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Earnings Scheduled For April 29, 2026

Bausch & Lomb Q1 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $1.244B Beat $1.218B Estimate

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

Bausch + Lomb Releases 2025 Sustainability Impact Report

12 Health Care Stocks Moving In Tuesday's After-Market Session

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Bausch + Lomb Announces Third-Quarter 2025 Results